期刊文献+

非小细胞肺癌胸腔镜与常规开胸术后血清VEGF、MMP-9变化的研究 被引量:19

Changes in Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 After Video-assisted Thoracoscopic Surgery and Thoracotomic Lobectomy in the Treatment of Patients with Non-small Cell Lung Cancer
下载PDF
导出
摘要 背景与目的血管内皮生长因子(vascular endothelial growth factor,VEGF)及基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)是重要的促血管生成因子,它们在肺癌血管生成中起着非常重要的作用。本研究旨在探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者围手术期血清VEGF及MMP-9水平变化的规律,同时比较电视辅助胸腔镜手术(video-assisted thoracoscopic surgery,VATS)及常规开胸手术(traditional open surgery,TOS)后上述指标变化的差异。方法选取卫生部北京医院胸外科2010年10月-2012年8月收治的NSCLC患者43例,入组患者均在全麻下行肺叶切除、系统淋巴结清扫术,所有患者均于术前1天、术后第1、2、3、7天抽取静脉血测定血清VEGF及MMP-9的水平,观察围手术期两指标的变化规律。根据手术方式的不同将入组患者分为胸腔镜组(VATS组,25例)及常规开胸组(TOS组,18例),比较两组围手术期血清VEGF及MMP-9变化的差异。结果 NSCLC患者术后血清VEGF及MMP-9水平均呈先升高后下降的趋势,分别于术后第2天、第3天达到峰值浓度,与术前相比有明显统计学差异(P=0.031,P=0.020),术后第7天时,两者水平仍高于术前。VATS组和TOS组两组术后VEGF及MMP-9水平也均出现先升高后下降的变化规律,变化幅度以TOS组明显,但两组间两指标变化趋势的差异均无统计学意义(F=2.022,P=0.163;F=1.703,P=0.199)。结论 NSCLC患者术后早期均出现血清VEGF及MMP-9水平的升高,变化幅度以TOS组略明显,但VATS与TOS组间的差异无统计学意义。 Background and objective Vascular endothelial growth factor (VEGF) and matrix metalloprotein- ase-9 (MMP-9) are important factors in angiogenesis. These factors function in the angiogenesis of lung cancers. The aim of this study is to determine the changes in serum VEGF and MMP-9 after patients with NSCLC were subjected to lobectomy. The aim of this study is also to compare the differences in the changes observed between video-assisted thoracoscopic surgery (VATS) and traditional open surgery (TOS). Methods A total of 43 consecutive patients with NSCLC were recruited from October 2010 to August 2012. All of these patients underwent lobectomy and systematic mediastinal lymphadenectomy. Blood was drawn from these patients to measure the serum levels of VEGF and MMP-9 in the morning before surgery and on postoperative days 1, 2, 3, and 7 (POD1, POD2, POD3, and POD7, respectively). Perioperative variations in serum VEGF and MMP-9 were also observed. Using different surgical options, we divided the patients into two groups: VATS group (25 patients) and TOS group (18 patients).the differences in the changes in serum VEGF and MMP-9 were then compared be- tween the two groups. Results After surgery, the serum VEGF and MMP-9 of patients with NSCLC initially increased and subsequently decreased. The peak levels were observed on POD2 and POD3, and these levels were significantly higher than the preoperative levels (P=0.031, P=0.020). On POD7, the serum VEGF and MMP-9 remained higher than the preopera- tive levels. In VATS and TOS groups, the serum VEGF and MMP-9 levels also initially increased and subsequently decreased. The TOS group showed a more evident variation. However, no significant statistical differences in the changes of VEGF and MMP-9 were found between the two groups (F=2.022, P=0.163; F=1.703, P=0.199). Conclusion Serum VEGF and MMP-9 remarkably increase in TOS group and VATS group. Although the serum level of VEGF an MMP-9 in TOS group were higher than that in VATS group. But no significant difference was observed between VATS and TOS group.
出处 《中国肺癌杂志》 CAS 北大核心 2014年第1期24-29,共6页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 胸腔镜 VEGF MMP-9 Lung neoplasms Video-assisted thoracoscopic surgery VEGF MMP-9
  • 相关文献

参考文献15

  • 1Jantus-Lewintre E, Sanmartin E, Sirera R, et al. Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer, 2011, 74(2): 326-331.
  • 2Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung, 2005, 183(1): 29-42.
  • 3Laack E, Kohler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small- cell lung cancer. Ann Oncol, 2002, 13(10): 1550-1557.
  • 4Whitson BA, Andrade RSj Boettcher A, et al. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage i non-small cell lung cancer. Ann Thorac Surg, 2007, 83(6): 1965-1970.
  • 5Nicastri DG, Wisnivesky JP, Litle VR, et al. Thoracoscopic lobectomy: Report on safety, discharge independence, pain, and chemotherapy tolerance.J Tnorac Cardiovasc Surg, 2008, 135(3): 642-647.
  • 6Kondo S, Asano M, Matsuo K, et al. Vascular endothelial growth factor/ vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta, 1994, 1221(2): 211-214.
  • 7Fleitas T, Martinez-Sales V, Vila V, et al. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer. Clin Transl Oncol, 2013, 15(11): 897-902.
  • 8Laack E, Scheffler A, Burkholder I, et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels inpatients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 2005, 50(1): 51-58.
  • 9Levi E, Fridman R, Miao HQ, et al. Matrix metalloproteinase 2 releases active solube ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA, 1996, 93(14): 706%7074.
  • 10Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol, 2000, 2(10): 737-744.

二级参考文献25

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2Takahama M , Tsutsumi M , Tsujiuchi , et al . Frequent exPression of the vascular endothelial growth factor in human non - small - cell lung cancers[J] . TPn J Clin Oncol ,2004,28(3) :176 - 181.
  • 3[1]Leung DW,Cachianes G,Kuang WJ,et al.Vascular endothelial growth factor is a secreted angiogenic mitognn.Science,1989,246(4935):1306-1309.
  • 4[2]Folkman J.What is the evidence that tumors are angingenesis dependent?J Natl Cancer Inst,1990,82(1):4-6.
  • 5[3]Weidner N,Folkman J,Pozza F.Tumor angiogenesis:a new significant and independent prognostic indicator in early-stage breast carcinoma.J Natl Cancer lnst,1992,84(24):1875-1887.
  • 6[4]Bicknell R,Harris AL.Novel growth regulatory factors and tumor angiogcnesis.Eur J Cancer,1991,27(6):781-785.
  • 7[5]Cox G,Jones JL,Andi A,et al.A biological staging model for operable non-small lung cancer.Thorax,2001,56(7):561-566.
  • 8[6]Aikawa H,Takahashi H,Fujimura S,et al.Immunohistoehemical study of tumor angiogenie factors in non-small cell lung cancer.Anticancer Res,1999,19(5B):4305-4309.
  • 9[7]Shou Y,Hirano T,Gong Y,et al.Influence of angiogenetic factors and matrix metalloproteinase upon tumor progression in non-small long cancer.Br J Cancer,2001,85(11):1706-1712.
  • 10[8]Adams J,Carder P J,Downey S,et al.Vascular endothelial growth factor(VEGF) in breast cancer:,comparison of plasma,serum,and tissue VEGF and microvessel density and effects of tamxifen.Cancer Res,2000,60(11):2898-2905.

共引文献16

同被引文献166

  • 1张新宇,王绍清.叉头盒蛋白M1和基质金属蛋白酶-2在非小细胞肺癌中的表达及意义[J].中国老年学杂志,2014,34(11):2922-2924. 被引量:4
  • 2陈伟,王贵玉,陈瑛罡,姜争,刘正,王猛,王洪伟,徐永鹏,王锡山.1810例左、右半结肠癌临床病理分析[J].中华结直肠疾病电子杂志,2013,2(4):162-165. 被引量:7
  • 3朱震,陈兵.CD166在非小细胞肺癌转移淋巴结中的表达及意义[J].山东医药,2013,53(37):56-57. 被引量:3
  • 4保红平,杨浩雷,高瑞岗,李奎,周娟娟,姚永良,方登华.腹部外科手术后肠内营养支持的临床研究[J].中华消化外科杂志,2007,6(1):32-34. 被引量:34
  • 5王京,徐娟,陈加媛,等.艾拉光动力疗法治疗中度和重度宫颈上皮内瘤变7例[J].皮肤性病诊断学杂志,2011,18(1):40-44.66.
  • 6Zoli M. Efficacy of a surveillance program for early detection of hepatoeel-lular carcinoma. Cancer, 1996,78 : 977-985.
  • 7Kanoh Y, Abe T, Masuda N, Akahoshi T.Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A[J]. Oncol Rep,2013,29(2):469-473.
  • 8Hirayama N, Tabata C, Tabata R, et al. Pleural effttsion VEGF lev-els as a prognostic factor of malignant pleural mesothelioma [J].RespirMed, 2011,105(1): 137-142.
  • 9Cheng D, Kong H,Li Y. Prognostic values of VEGF and IL-8 inmalignant pleural effusion in patients with lung cancer [J]. Biomark-ers, 2013,18(5):386-390.
  • 10Bradshaw M, Mansfield A, Peikert T. The role of vascular endothe-lial growth factor in the pathogenesis, diagnosis and treatment of-malignant pleural effusion [J]. Curr Oncol Rep, 2013,15(3):207-216.

引证文献19

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部